Your browser doesn't support javascript.
loading
Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
Galateau Salle, Francoise; Le Stang, Nolwenn; Tirode, Franck; Courtiol, Pierre; Nicholson, Andrew G; Tsao, Ming-Sound; Tazelaar, Henry D; Churg, Andrew; Dacic, Sanja; Roggli, Victor; Pissaloux, Daniel; Maussion, Charles; Moarii, Matahi; Beasley, Mary Beth; Begueret, Hugues; Chapel, David B; Copin, Marie Christine; Gibbs, Allen R; Klebe, Sonja; Lantuejoul, Sylvie; Nabeshima, Kazuki; Vignaud, Jean-Michel; Attanoos, Richard; Brcic, Luka; Capron, Frederique; Chirieac, Lucian R; Damiola, Francesca; Sequeiros, Ruth; Cazes, Aurélie; Damotte, Diane; Foulet, Armelle; Giusiano-Courcambeck, Sophie; Hiroshima, Kenzo; Hofman, Veronique; Husain, Aliya N; Kerr, Keith; Marchevsky, Alberto; Paindavoine, Severine; Picquenot, Jean Michel; Rouquette, Isabelle; Sagan, Christine; Sauter, Jennifer; Thivolet, Francoise; Brevet, Marie; Rouvier, Philippe; Travis, William D; Planchard, Gaetane; Weynand, Birgit; Clozel, Thomas; Wainrib, Gilles.
Afiliación
  • Galateau Salle F; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France. Electronic address: francoise.galateau@lyon.unicancer.fr.
  • Le Stang N; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Tirode F; University Claude Bernard Lyon, INSERM, CNRS, Research Cancer Center of Lyon, Centre Léon Bérard, Lyon, France.
  • Courtiol P; OWKIN Paris, France.
  • Nicholson AG; Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Tsao MS; University Health Network, Princess Margaret Cancer Centre and University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada.
  • Tazelaar HD; Mayo Clinic, Scottsdale, Arizona.
  • Churg A; Columbia University and Department of Pathology Vancouver, Canada.
  • Dacic S; FISH and Developmental Laboratory at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Roggli V; Duke University Medical Center, Department of Pathology, Durham, North Carolina.
  • Pissaloux D; Department of BioPathology-FISH Laboratory, Centre Leon Berard Lyon, France.
  • Maussion C; OWKIN Paris, France.
  • Moarii M; OWKIN Paris, France.
  • Beasley MB; Mount-Sinai Medical Center, Department of Pathology, New York, New York.
  • Begueret H; CHU Bordeaux, Haut Leveque Hospital, Department of Pathology, Bordeaux, France.
  • Chapel DB; University of Chicago, Department of Pathology, Chicago, Illinois.
  • Copin MC; University. Lille-CHU, Department of Pathology, Lille, France.
  • Gibbs AR; University of Wales, Department of Cellular Pathology, Cardiff, United Kingdom.
  • Klebe S; Department of Anatomical Pathology, Flinders University, Adelaide, Australia.
  • Lantuejoul S; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Nabeshima K; Department of Pathology, Fukuoka University School of Medicine and Hospital, Fukuoka, Japan.
  • Vignaud JM; CHU Nancy, INSERM, University of Lorraine, Lorraine, France.
  • Attanoos R; University of Wales, Department of Cellular Pathology, Cardiff, United Kingdom.
  • Brcic L; Department of Pathology, Graz, Austria.
  • Capron F; CHU Pitié Salpétrière Paris, Department of Pathology, Paris, France.
  • Chirieac LR; Brigham and Women's Hospital, Boston, Massachusetts.
  • Damiola F; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Sequeiros R; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Cazes A; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Bichat Department of Pathology, University Paris VII, Paris, France.
  • Damotte D; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Cochin-Hotel Dieu, Department of Pathology, Paris, France.
  • Foulet A; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CH Le Mans, Department of Pathology, Pays de la Loire, France.
  • Giusiano-Courcambeck S; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Hospital Nord, Marseille, University Aix-Marseille, Marseille, France.
  • Hiroshima K; Tokyo Women's Medical University, Department of Pathology, Tokyo, Japan.
  • Hofman V; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Mayo Clinic, Scottsdale, Arizona; CHU Nice, Department of Clinical and Experimental Pathology (LPCE), Nice, France.
  • Husain AN; University of Chicago, Department of Pathology, Chicago, Illinois.
  • Kerr K; Aberdeen Royal Infirmary, Department of Pathology, Aberdeen, Scotland.
  • Marchevsky A; Scotland Cedars-Sinai Medical Center, Department of Pathology, Los Angeles, California.
  • Paindavoine S; University Claude Bernard Lyon, INSERM, CNRS, Research Cancer Center of Lyon, Centre Léon Bérard, Lyon, France.
  • Picquenot JM; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Department of Pathology, Henri Becquerel Centre, Rouen, France.
  • Rouquette I; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; IUCT-Oncopôle, Department of Pathology, Toulouse, France.
  • Sagan C; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Nantes, INSERM, Thorax Institute, Hôpital Laënnec CHU Nantes, Nantes, France.
  • Sauter J; Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.
  • Thivolet F; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Hospices Civils, East Hospital Group, Department of Pathology, Lyon, France.
  • Brevet M; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Hospices Civils, East Hospital Group, Department of Pathology, Lyon, France.
  • Rouvier P; CHU Pitié Salpétrière Paris, Department of Pathology, Paris, France.
  • Travis WD; Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.
  • Planchard G; MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Department of Pathology, CHU Caen, Caen, France.
  • Weynand B; UZ Leuven, Department of Pathology, Leuven, Belgium.
  • Clozel T; OWKIN Paris, France.
  • Wainrib G; OWKIN Paris, France.
J Thorac Oncol ; 15(6): 1037-1053, 2020 06.
Article en En | MEDLINE | ID: mdl-32165206
ABSTRACT

INTRODUCTION:

Histologic subtypes of malignant pleural mesothelioma are a major prognostic indicator and decision denominator for all therapeutic strategies. In an ambiguous case, a rare transitional mesothelioma (TM) pattern may be diagnosed by pathologists either as epithelioid mesothelioma (EM), biphasic mesothelioma (BM), or sarcomatoid mesothelioma (SM). This study aimed to better characterize the TM subtype from a histological, immunohistochemical, and molecular standpoint. Deep learning of pathologic slides was applied to this cohort.

METHODS:

A random selection of 49 representative digitalized sections from surgical biopsies of TM was reviewed by 16 panelists. We evaluated BAP1 expression and CDKN2A (p16) homozygous deletion. We conducted a comprehensive, integrated, transcriptomic analysis. An unsupervised deep learning algorithm was trained to classify tumors.

RESULTS:

The 16 panelists recorded 784 diagnoses on the 49 cases. Even though a Kappa value of 0.42 is moderate, the presence of a TM component was diagnosed in 51%. In 49% of the histological evaluation, the reviewers classified the lesion as EM in 53%, SM in 33%, or BM in 14%. Median survival was 6.7 months. Loss of BAP1 observed in 44% was less frequent in TM than in EM and BM. p16 homozygous deletion was higher in TM (73%), followed by BM (63%) and SM (46%). RNA sequencing unsupervised clustering analysis revealed that TM grouped together and were closer to SM than to EM. Deep learning analysis achieved 94% accuracy for TM identification.

CONCLUSION:

These results revealed that the TM pattern should be classified as non-EM or at minimum as a subgroup of the SM type.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprendizaje Profundo / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprendizaje Profundo / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article